Earlier this week, we highlighted Pfizer (FPE) at $34.63. It’s set to open at $35.85 today.
We highlighted BioNTech (BNTX) at $78.38. It’s set to open at $87.45 today.
And just yesterday, we again highlighted Moderna (MRNA), as it traded at $74. That was hours before the company’s COVID-1 vaccine was found to induce immune responses in every volunteer in a Phase 1 study.
“These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects — fatigue, chills, headache, muscle pain, pain at the injection site — becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal,” says CNN.
As of this morning, MRNA is set to open at $88.15. That’s a win of just over $14 in a day.
Congratulations. We’d love to hear how you did with these opportunities.
As for new ideas, take a look at Rigel Pharmaceuticals (RIGL).
The company just announced a UK trial for a potential COVID-19 treatment.
“The Imperial College London will operate the open-label, controlled trial for Tavalisse, which received Food and Drug Administration approval for chronic immune thrombocytopenia in 2018,” says MarketWatch. “Patients will receive Tavalisse, the chemotherapy ruxolitinib, or the standard of care, with a goal of understanding whether the drug can prevent the progression of mild or moderate COVID-19 pneumonia to more severe disease.”